At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,083 enrolled
Drug / intervention
Empagliflozin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries
In Brief
An observational study evaluating Empagliflozin, Sodium Glucose Transporter 2 inhibitor, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 4,083 participants across 177 sites in 5 countries.
Detailed Summary
This is a non-interventional study using existing data including medical chart review.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesBulgaria, Czechia, Hungary, Poland, Russia
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartAug 2019
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 17, 2019
Enrollment StartAug 26, 2019
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.5 years ago
Interventions
Empagliflozindrug
Empagliflozin
Sodium Glucose Transporter 2 inhibitordrug
Sodium Glucose Transporter 2 inhibitor
Dipeptidyl-peptidase 4 inhibitordrug
Dipeptidyl-peptidase 4 inhibitor
Glucagon-like peptide 1 agonistdrug
Glucagon-like peptide 1 agonist